Mujahed Khan Pathan’s Post

View profile for Mujahed Khan Pathan, graphic

Jr. Manager Regulatory Affairs | Master of Technology (M.Tech)

Understanding Drug Safety: EMA vs. USFDA on Nitrosamine Guidelines Explore key points about how European and U.S. agencies manage drug safety for nitrosamines: - Scope: EMA covers a wide range of products; USFDA focuses on specific drug types. - Safety Measures: Both discuss safety, but with different priorities and details. - Testing and Risk: EMA focuses on developing methods; USFDA emphasizes testing validation. - Setting Safety Limits: EMA uses broad data; USFDA sets specific intake limits. For a full comparison, check the linked table in the comments. 🔍 Any discrepancies or thoughts? Drop a comment below! 🔄 Feel free to share this post! #Regulations #pharma, #regulatory #pharmaindustry #EMA #fda #eu #CDSCO #Healthcare #kaust #eda #algeria #safety #nitrosamine #usfda #sfda #gcc #middleeast #knowledgesharing #learning

Dr. Kiran Avadhani M Pharm, Ph D

Head, Drug Product Development of Biosimilars

7mo

Very informative

Muna Kamal

Certified GCC regulatory affairs specialist

7mo

Very informative

See more comments

To view or add a comment, sign in

Explore topics